Emerson Electric on Pace for Largest Percent Increase Since June 2022 — Data Talk
Emerson Electric Co. (EMR) is currently at $96.26, up $4.03 or 4.37%
--Would be highest close since Oct. 16, 2023, when it closed at $96.35
--On pace for largest percent increase since June 24, 2022, when it rose 5.45%
--Currently up six consecutive days; up 9.76% over this period
--Longest winning streak since Oct. 28, 2022, when it rose for six straight trading days
--Best six day stretch since the six days ending Nov. 10, 2022, when it rose 10.65%
--Up 8.28% month-to-date
--Up 0.21% year-to-date
--Down 8.93% from its all-time closing high of $105.70 on Sept. 2, 2021
--Up 1.06% from 52 weeks ago (Dec. 15, 2022), when it closed at $95.25
--Down 3.86% from its 52-week closing high of $100.12 on Sept. 11, 2023
--Up 23.92% from its 52-week closing low of $77.68 on May 31, 2023
--Traded as high as $96.59; highest intraday level since Oct. 17, 2023, when it hit $96.96
--Up 4.73% at today's intraday high; largest intraday percent increase since Aug. 2, 2023, when it rose as much as 7.54%
All data as of 2:06:38 PM ET
Source: Dow Jones Market Data, FactSet
(END) Dow Jones Newswires
December 14, 2023 14:23 ET (19:23 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track